Despite advances that have improved the treatment of chronic myeloid leukemia (CML) patients in chronic phase, the mechanisms of the transition from chronic phase CML to blast crisis (BC) are not ...

The metastasis suppressor 1 (Mtss1) protein acts a tumour suppressor in chronic myeloid leukaemia (CML) stem cells, reveals research published in Leukemia. Using a double transgenic mouse model of CML ...

The author has reported existing financial interest in, or relationships with, the following manufacturers of products or providers: Novartis Pharmaceuticals, Inc. Dr. Kolibaba is Instructor of ...

Bosutinib approved for chronic myelogenous leukemia The FDA has approved bosutinib (Bosulif, Pfizer) for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML, who are ...